What is Rein Therapeutics, Inc. (RNTX) stock price today?

Rein Therapeutics, Inc. (RNTX) is currently trading at $0.79, up 3.21% today.

What is RNTX P/E ratio?

Rein Therapeutics, Inc.'s P/E ratio is -0.44. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is RNTX return on equity (ROE)?

Rein Therapeutics, Inc.'s return on equity (ROE) is -234.45%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Rein Therapeutics, Inc.'s market cap?

Rein Therapeutics, Inc. has a market capitalization of $22.20M.

NASDAQ · Medical - Pharmaceuticals

Rein Therapeutics, Inc. (RNTX) Stock

$0.79 +3.21% NASDAQ: RNTX Healthcare

Valuation

Metric	Value
Price	$0.79
Market Cap	$22.20M
P/E Ratio	-0.44
P/B Ratio	2.38
P/S Ratio	0.00
EPS (TTM)	$-1.96
52-Week High	$2.18
52-Week Low	$0.69
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-234.45%
ROA	-75.43%
ROCE	-36.89%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.00
Current Ratio	0.67

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$0	$0
Operating Profit	$0	$0	$0	$-65.0M	$-22.0M
Net Profit	$0	$0	$0	$-63.0M	$-50.0M
EPS	$-5.89	$-6.02	$-3.42	$-3.51	$-1.96
Op Margin	—	—	—	—	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$48.0M	$22.0M	$106.0M	$69.0M	$24.0M
Total Liabilities	$5.0M	$3.0M	$99.0M	$15.0M	$7.0M
Cash	$4.0M	$5.0M	$17.0M	$13.0M	$3.0M
Borrowings	$0	$0	$0	$0	$0

Latest News

Rein Therapeutics Completes Global Expansion of Phase 2 IPF Trial MT Newswires · Jul 21, 2026 Rein Therapeutics Announces Phase 2 RENEW Trial Now Enrolling Across All Five Countries GlobeNewswire · Jul 21, 2026 All You Need to Know About Rein Therapeutics Inc. (RNTX) Rating Upgrade to Buy Zacks · Jun 17, 2026 Rein Therapeutics Expands Phase 2 RENEW Trial into United Kingdom GlobeNewswire · Jun 11, 2026 Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option GlobeNewswire · May 18, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-24.0M	$-25.0M	$-20.0M	$-22.0M	$-19.0M
Investing Cash Flow	$-36.0M	$26.0M	$16.0M	$0	$0
Financing Cash Flow	$0	$0	$16.0M	$7.0M	$0
Net Cash Flow	$-4.0M	$2.0M	$12.0M	$-4.0M	$-10.0M
Free Cash Flow	$-24.0M	$-25.0M	$-20.0M	$-22.0M	$-19.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	-0.01
EV / EBITDA	-0.66
FCF Yield	-84.13%
Quick Ratio	4.27
Interest Coverage	0.00
Return 1Y	-32.41%
Return 3Y	-51.23%
Return 5Y	-95.49%

Ownership

Insiders Held5.37%

Institutions Held20.85%

Institutions Float Held22.04%

Institutional Holder	Shares	Report Date
Voss Capital, LP	4,388,362	2026-03-31
Bios Capital Management, LP	1,982,375	2026-03-31
Vanguard Capital Management LLC	998,521	2026-03-31
University of Texas/Texas AM Investment Managment Co	511,610	2026-03-31
Cable Car Capital, LP	420,000	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ATNMActinium Pharmaceuticals, Inc. (Delaware)	$1.10	+1.85%	3.25	$34.51M	0.00%
BCAB	$1.74	+0.00%	-0.12	$2.88M	0.00%
BEATHeartbeam, Inc.	$0.48	-1.74%	-0.84	$26.65M	0.00%
CELUCelularity Inc.	$1.56	+6.85%	-0.51	$45.16M	0.00%
KZR	$7.29	+0.00%	-0.96	$53.86M	0.00%

About Rein Therapeutics, Inc.

Rein Therapeutics, Inc. is led by CEO James Brian Windsor, employs 11 people, headquartered in US, publicly traded since 2017.

Rein Therapeutics, Inc. (RNTX) stock trades at $0.79 with a market capitalization of $22.20M. The stock is valued at a price-to-earnings (P/E) ratio of -0.44, price-to-book of 2.38, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.69 and $2.18, and currently trades 63.8% below its 52-week high.

On profitability, Rein Therapeutics, Inc. generates a return on equity (ROE) of -234.45%, return on capital employed of -36.89%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides